Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Chlorprothixene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.58 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | HRH1 | P35367 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | HTR6 | P50406 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorprothixene SCHEMBL30383335 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL29626798 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL94236 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL29357955 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL24133 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL455759 | 0.99 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL29857011 | 0.99 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL455758 | 0.99 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL3491182 | 0.92 | LMNA (0.84) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL29462906 | 0.90 | LMNA (0.84) | LMNACYP3A4CYP2D6DRD2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9946 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | HADASIT MED RES SERVICE (IL) | 2026-03-26 | — | — | US | claimed |
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | UNIVERSITY OF CINCINNATI (US) | 2026-02-17 | — | — | US | claimed |
| US-20260034065-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2026-02-05 | — | — | US | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| US-12527754-B2 | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions | TUFTS MEDICAL CENTER, INC. (US) | 2026-01-20 | — | — | US | claimed |
| EP-4658278-A1 | SELECTIVE FIASMA TREATMENT | Valo Health, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| US-12472146-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2025-11-18 | — | — | US | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| US-20250295671-A1 | Hazardous Agent Injection System | ANTARES PHARMA, INC. (US) | 2025-09-25 | — | — | US | claimed |
| WO-1994023700-A1 | HIGH RELEASE SOLID PREPARATION, PREPARATION AND USE THEREOF | RIJKSUNIVERSITEIT GENT LABORATORIUM VOOR FARMACEUTISCHE TECHNOLOGIE (BE) | 1994-10-27 | — | — | WO | claimed |
| EP-0428754-B1 | HAIR GROWTH STIMULANT | SHISEIDO CO LTD (JP) | 1994-05-25 | — | — | EP | claimed |
| EP-0580776-A1 | USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-02-02 | — | — | EP | claimed |
| WO-1992018127-A1 | USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-10-29 | — | — | WO | claimed |
| EP-0428754-A1 | HAIR GROWTH STIMULANT | SHISEIDO COMPANY LIMITED (JP) | 1991-05-29 | — | — | EP | claimed |
| US-4443446-A | Use of psychoactive drugs as vaginal contraceptives | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1984-04-17 | — | — | US | claimed |
| EP-0082203-A1 | USE OF CALMODULIN BINDING DRUGS IN UTERUS TO PREVENT PREGNANCY | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1983-06-29 | — | — | EP | claimed |
| WO-1983000086-A1 | USE OF CALMODULIN BINDING DRUGS IN UTERUS TO PREVENT PREGNANCY | UNIV GEORGIA RES FOUND (US) | 1983-01-20 | — | — | WO | claimed |
| EP-0053108-A1 | VAGINAL CONTRACEPTIVES COMPRISING PSYCHOACTIVE DRUGS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1982-06-09 | — | — | EP | claimed |
| WO-1981003421-A1 | USE OF PSYCHOACTIVE DRUGS AS VAGINAL CONTRACEPTIVES | UNIV GEORGIA (US) | 1981-12-10 | — | — | WO | claimed |